NDAORAL-28TABLET
Approved
Nov 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+80 is an oral combined estrogen-progestin contraceptive containing mestranol and norethindrone, approved in 1968. It prevents pregnancy through ovulation suppression and cervical mucus thickening. This is a legacy oral contraceptive product from Pfizer's portfolio.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on niche patient retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORINYL 1+80 offers limited career advancement opportunities given its mature lifecycle and approaching loss of exclusivity. Roles focus primarily on defending market share, managing generic competition, and ensuring supply continuity rather than driving innovation or revenue growth.
Brand Manager (legacy portfolio)Regulatory Affairs Specialist
Worked on NORINYL 1+80 28-DAY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.